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ABSTRACT  
Objective: Neuroimaging studies show structural alterations of various brain regions in children and adults with ADHD, 
although non-replications are frequent. Our aim is to identify cortical characteristics related to ADHD using large-scale 
studies. Methods: Cortical thickness and surface area (based on the Desikan–Killiany atlas) were compared between cases 
(n=2246) and controls (n=1934) for children, adolescents, and adults separately in ENIGMA-ADHD, a consortium of 36 
centers. To assess familial effects on cortical measures, cases, unaffected siblings, and controls in the NeuroIMAGE study 
(n=506) were compared. Associations of the attention scale from the Child Behavior Checklist with cortical measures were 
determined in a pediatric population sample (Generation-R, n=2707). Results: In ENIGMA-ADHD, lower surface area values 
were found in children with ADHD, mainly in frontal, cingulate, and temporal regions; the largest effect was for total surface 
area (Cohen’s d=-0.21; pFDR=<0.001). Fusiform gyrus and temporal pole cortical thickness was also lower in children with 
ADHD. Neither surface area nor thickness differences were found in the adolescents/adult groups. Familial effects were 
seen for surface area in several regions. In an overlapping set of regions, surface area, but not thickness, was associated 
with attention problems in Generation-R. Conclusion: Subtle differences in cortical surface area are widespread in children, 
but not in adolescents and adults with ADHD, confirming involvement of frontal cortex and highlighting regions deserving 
further attention. Importantly, the alterations behave like endophenotypes in families and are linked to ADHD symptoms in 
the population, extending evidence that ADHD behaves as a continuous trait in the population. Future longitudinal studies 
should clarify individual lifespan trajectories that lead to non-significant findings in adolescent/adult groups despite 
presence of an ADHD diagnosis.  
KEYWORDS: ADHD, cortical thickness, cortical surface area, lifespan, meta-analysis, imaging  
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INTRODUCTION 
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder characterized by age-inappropriate 
levels of inattention and/or hyperactivity and impulsivity. ADHD occurs in around 5-7% of children and 2.5% of adults (1, 2). 
ADHD can negatively affect multiple aspects of daily life of patients, and represents a major public health challenge (3). 
Neuroimaging studies in ADHD show differences between the brains of people with ADHD and those of healthy individuals 
in structure (4-9), function (8, 10, 11), and connectivity (12-14), albeit with small effect sizes (9). While informative, existing 
studies have several major limitations. First, most ADHD neuroimaging studies have been cross-sectional and performed 
during childhood; studies that either consider ADHD throughout the lifespan or have a longitudinal design are rare. In one 
such lifespan study, we recently showed that differences in intracranial volume (ICV) and subcortical volumes between 
patients and healthy individuals were largely restricted to childhood (9). Furthermore, an earlier longitudinal study showed 
slower, delayed development of cortical thickness and surface area in children with ADHD, especially in frontal-temporal 
regions (15). Nonetheless, large-scale studies of cerebral cortical architecture throughout the lifespan are lacking. 
A second major limitation in the neuroimaging literature is that most studies on ADHD have small sample sizes and show 
limited reproducibility (16). Combining data from existing research by means of meta-/mega-analysis can produce more 
reliable results. For ADHD, meta-/mega-analyses of structural brain phenotypes are available for subcortical structures (9, 
17), but the cortex has only been assessed in meta-analyses of brain-wide voxel-based morphometry (VBM) studies (5-8). 
The largest VBM study (931 patients and 822 controls) reported case-control differences for anterior cingulate, medial 
prefrontal cortex, ventromedial orbitofrontal cortex, and the insula (8). Here, we further the field by providing the first 
large-scale, mega-analytic examination of cortical measures across the lifespan in ADHD. We analyzed cortical surface area 
and thickness separately, as recent large-scale studies show that the biological mechanisms underlying such measures 
overlap only partially (18). Our large sample size also provides the power needed to examine clinical factors such as 
common comorbid disorders. 
Neuroimaging analyses of ADHD have also largely not addressed a major question: are the observed brain differences a 
consequence of living with the disorder, or do the brain differences reflect underlying risk for the disorder? Different study 
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designs can help us begin to address this question. Family-based studies can indicate if cortical changes are present in 
unaffected siblings of cases to indicate the involvement of shared genetic and/or environmental risk factors that underlie 
the cortical characteristics associated with the disorder. Several family studies (e.g. (19)) suggest that at least some of the 
brain alterations seen in patients are also present in their unaffected siblings and are associated with symptom severity in 
healthy individuals. Population-based studies can determine whether individuals with traits of ADHD show similar cortical 
changes to those associated with the full syndrome. The largest population study published to date (n=776 children) 
showed that higher levels of ADHD symptoms were associated with a thinner cortex in caudal middle frontal, temporal, and 
occipital regions (20). While this and similar studies (21) showed that brain alterations extend beyond the clinical disorder, 
no attempts have yet been made to directly assess the overlap between studies in clinical samples and the general 
population. Combined, family and population-based findings suggest that the brain differences seen in those with ADHD are 
not simply markers of the disorder, but larger studies, directly comparing brain phenotypes across different informative 
study designs, are needed to shed more light on this. 
Here, we present a mega-analysis of cortical thickness and surface area in participants with ADHD and healthy controls 
across the lifespan from the ENIGMA-ADHD Working Group, a world-wide collaboration aiming to characterize the 
characteristics of the brain of people with ADHD. All partners used standardized methods (segmentation protocols and 
quality control procedures), limiting methodological heterogeneity more than in previous meta-analyses. In addition to 
assessing case-control differences in children, adolescents, and adults, we investigated cortical brain correlates of clinical 
features, assessed familiality of effects, and mapped the dimensionality of affected cortical regions in the large, 
independent pediatric Generation-R population study (22).  
 
MATERIALS AND METHODS 
Contributing studies 
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The ENIGMA-ADHD Working Group currently consists of 36 cohorts from around the world 
(http://enigma.ini.usc.edu/ongoing/enigma-adhd-working-group/). All cohorts have structural imaging data available for 
individuals with an ADHD diagnosis, and most sites also include data from healthy controls. An overview of the sites is given 
in ST1; details of image acquisition and study protocols are provided in ST2 and SA1. The dataset for the cortical analysis 
comprised 4,180 individuals: 2,246 people with ADHD with mean age of 19.22 years (SD= 11.31), age range of 4-62 years, 
74.1% males; 1,934 healthy controls with mean age of 18.05 years (SD=11.26), age range of 4-63 years,  59.8% males.  
For the analysis of dimensionally-assessed ADHD traits in the general population we used data from 2,707 individuals with 
mean age of 10.11 (SD=0.57) years, age range of 8.5-11.9 years, 49.4% males (ST3) from the Generation-R cohort (22). 
For all participating cohorts, approval for the analysis was available from the responsible ethics committees.  
 
Neuroimaging  
Structural T1-weighted brain MRI data were acquired and processed at the individual sites. The images were analyzed using 
standardized protocols to harmonize analysis and quality control processes (http://enigma.ini.usc.edu/protocols/imaging-
protocols/ and SA2) (23-25). Fully-automated and validated neuroimaging segmentation algorithms based on FreeSurfer 
versions 5.1 or 5.3 were used (ST2). Regions based on the Desikan–Killiany atlas were segmented, which resulted in cortical 
thickness and surface area values for 34 left and 34 right hemisphere regions. Two whole-hemisphere values for average 
thickness and average surface area were also computed. For further analysis, we used the mean of the bilateral values 
((R+L)/2).  
The Generation-R data were collected using a single, study-dedicated MRI scanner and processed using FreeSurfer version 
6.0 on a high-performance computing system (Cartesius, surfsara.nl), for scanner sequence please see SA3. All imaging data 
were visually inspected for inaccuracies in the surface-based reconstruction. Data not suitable for analysis were excluded 
(for a flowchart see SF1), providing n=2707. For a non response analysis, please see SA4. 
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Case-control differences in cortical thickness and surface area in children, adolescents, and adults 
Based on the age-specificity of earlier findings (9), three age groups were assessed: children: 4-14 years, 1081 cases, 1048 
controls; adolescents: 15-21 years, 432 cases, 347 controls; adults: 22-63 years, 733 cases, 539 controls. As there are 
marked developmental changes across the 4 to 14 year age range, we also performed supplemental analyses on age tertiles 
of the childhood group. For each of the age groups we determined differences between participants with ADHD and 
healthy controls using mixed-effect models with ‘site’ as a random factor in the nlme package in R. Age and sex were 
included as additional covariates; for the surface area analysis, intracranial volume (ICV) was also added, as surface area 
scales with head size (24-26). We also include analyses without ICV as a covariate given the debate over whether it should 
be included as a covariate (see SA5). To calculate Cohen’s d effect size estimates, adjusting for the appropriate covariates, 
we used the t-statistic from the Diagnosis (ADHD=1, control=0) predictor in the equation(27). To correct for multiple 
comparisons, we used a false discovery rate (FDR) at q=0.05.  
 
Split-half validation of case-control findings 
To ensure stability of effects, we performed a validation of our mega-analysis in age groups with significant results. Data 
were split into two halves, statistically matched for age, sex, and ICV within each site. Validation was defined as pFDR<0.05 in 
the first half and puncorrected<0.05 in the second half, with matching effect directions(28).  
 
Exploration of the influence of sex, IQ and clinical factors on cortical regions affected in ADHD  
For regions and age groups showing validated case-control differences, we examined potential effects of sex, IQ, comorbid 
disorders, medication use and ADHD symptoms (severity) (see details in SA6). Given the exploratory nature of these 
analyses, we report uncorrected p-values in the Results section. 
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Family study  
Two subsets of the ENIGMA-ADHD sample (NeuroIMAGE Amsterdam and Nijmegen (29)) had collected brain data from 
patients (n=211), their unaffected siblings (n=175), and unrelated controls (n=120). To determine familial effects on ADHD-
affected cortical regions, unaffected siblings were compared with healthy controls in those cortical regions. Levels of ADHD 
symptoms in the unaffected siblings had been shown to not differ from those of controls (19). Multiple comparisons 
correction was performed based on the effective number of independent tests (Meff) (30); differences between unaffected 
siblings and controls were considered significant at p<0.01 (Meff=5, for details please see SA7). 
 
Association between ADHD symptoms and the cortex in the general population  
ADHD symptoms were assessed in children from Generation-R using the Child Behavior Checklist (CBCL)(31). Both attention 
problems (Syndrome Scale) and ADHD problems (DSM-oriented scale) were examined for associations with 
surface/thickness in regions with validated case-control differences in ENIGMA-ADHD. R statistical software (version 3.3.3) 
was used to fit multiple linear regressions to model these associations. Primary analyses were adjusted for age at MRI scan, 
sex, ICV and ethnicity. In supplemental analyses, models were additionally adjusted for non-verbal IQ, ADHD medication 
status, MR-scanner software version, and motion during scanning (SA8).  
 
RESULTS 
Case-control differences in cortical surface area and thickness in children, adolescents, and adults 
In children with ADHD versus control children, lower values of cortical surface area were widespread, with 24 out of 34 
regions and total surface area being smaller in patients (Table 1, Figure 1, ST4). The largest effect was found for total 
surface area: d= -0.21, pFDR=<0.001. When the child group was further subdivided in post-hoc analyses, this effect size 
increased to d=-0.35, pFDR=<0.001 in the youngest tertile (4-9 years), which comprised 317 cases and 340 controls (ST5). 
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Also more generally, the youngest group showed the largest case-control differences (ST5). No case-control differences 
were found in the adolescent and adult groups (ST6 and ST7; ST8 shows combined analysis of age groups). For results of the 
model without ICV, please see ST9. 
Cortical thickness was affected in four regions (fusiform, parahippocampal, and precentral gyrus and temporal pole) in 
children, all being thinner in patients than controls (Table 2, Figure 1 and ST10). Further subdivision of the child group 
retained significant effects for fusiform gyrus (d= -0.31, pFDR=0.002) and temporal pole (d=-0.25, pFDR=0.02) in the group of 
children aged 10 and 11 (356 cases, 365 controls); in younger (4-9 years) and older (12-14 years) children, effects did not 
survive multiple comparisons correction(ST11). In adolescents and adults, no case-control differences were found (ST12 and 
ST13; ST14 shows combined analysis of age groups).  
 
Validation of case-control findings 
The split-half validation analysis showed seven regions for surface area and two regions for thickness to be significant in 
both halves (Table 1 & 2, ST15 & ST16, Figure1). For all other regions, the direction of effects was the same in both split-
halves.  
Effect sizes of the validated cortical differences across the age groups are plotted in Figure 1, together with the effect sizes 
of subcortical brain volumes from our earlier work (9). Post-hoc analysis by adding the term Agegroup*Diagnosis to the 
main model indicated differences in effect sizes across the lifespan for surface area of the superior frontal gyrus and 
thickness of the fusiform gyrus (ST17). 
  
Exploration of effects of sex, IQ, comorbidity, psychostimulant medication, and ADHD severity  
Extending the main findings, we investigated several factors linked to ADHD, which have shown to influence brain volume 
in their own right. No significant interaction effects of diagnosis-by-sex were found (ST18). Correcting for IQ in surface area 
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analyses only led to minor changes in the level of significance in the case-control comparisons. In all thickness analyses, IQ 
was a non-significant contributor (ST19).  
For comorbidity analyses, we had information on cases of the childhood subset (n=1081) available (comorbidity ever versus 
never, lifetime) for almost 50% of participants (ST20). In total, 194 children with ADHD (39%) were ever or currently 
diagnosed with a comorbid psychiatric disorder. The three most frequently co-occurring disorders were oppositional 
defiant disorder (ODD, present in n=79 cases (16.0%)), anxiety disorders (observed in n=39 (8.6%)), and mood disorders 
(seen in n=13 (3.0%)). Presence versus absence of comorbid disorders did not affect cortical surface area; a nominal effect 
of ever being diagnosed with a comorbid psychiatric disorder was found for fusiform gyrus thickness, with a thinner 
fusiform gyrus in cases with an additional disorder in the past or present (ST21).  
Current stimulant use versus no current use had a nominally significant association with surface area of two regions in 
frontal cortex, with those taking medication having lower surface areas (ST21).  
 Hyperactivity/impulsivity severity ratings on Conners’ questionnaires, available for n=240 childhood patients, but not 
inattention, showed nominally significant correlation with surface area in rostral anterior cingulate cortex (r=-0.18, p=0.01), 
superior frontal gyrus (r=-0.19, p=0.01), and with total surface area (r=-0.15, p=0.03) (ST22). 
 
Family study  
Among the validated ADHD-associated cortical features, surface area of caudal middle frontal, lateral orbital frontal, and 
superior frontal gyrus and the total surface area were significantly smaller in the unaffected siblings as compared with 
controls (Figure 2, ST23), indicating familial effects. A similar trend was seen for the majority of the other cortical measures 
(SF2). 
 
Effects of ADHD symptoms in the general population on the validated brain phenotypes   
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Population-based analysis showed caudal middle frontal gyrus, middle temporal gyrus, and total surface area to be 
associated with the attention problems scale of the CBCL (Table3, SF3); higher levels of dimensional ADHD symptoms were 
associated with smaller surface areas. No associations were found with the two cortical thickness measures (Table 3). To 
ensure a linear fit was optimal and that the more severe end of the symptom continuum was not driving findings, models 
with quadratic and cubic symptom terms were also tested. AIC and BIC values were highly similar across models, suggesting 
little to no improvement over the simpler linear term (ST24).  
Adding non-verbal IQ or ADHD medication status to the analysis model of the attention problems, did not influence results 
(ST25). Results also remained stable when we tested the effect of MRI scanner software version and image quality (ST25). 
The quantitative amount of motion in the T1-weighted scan (32) did not seem to affect analyses (ST26).  
 
DISCUSSION 
Here, we report the largest study to date of ADHD and cortical surface area and thickness in clinical samples and a pediatric 
population sample. Compared with healthy controls, children with ADHD showed smaller surface area in frontal, temporal, 
and cingulate regions, with the effects being most prominent in the youngest children (4-9 years). Case control differences 
had small effect sizes, but survived validation. Differences in thickness were limited to the temporal pole and fusiform 
gyrus, which were thinner in children with ADHD. These differences were most prominent in the group aged 10 and 11 
years. The influence of comorbidity and symptom ratings, available from subsamples, appeared limited. None of these 
covariates of interest showed effects surviving multiple testing correction. There were no significant associations between 
cortical alterations and either stimulant treatment or IQ. Family-based analyses revealed familial effects for four surface 
area regions, but not for any thickness measures. A set overlapping with family-based analyses (caudal middle frontal gyrus, 
total surface area) and/or severity rating analyses (total surface area) showed associations with CBCL-based ratings of 
attention problems, in the population-based sample; no such effects were found for thickness.  
The regions affected in ADHD were widespread across the cortex. The frontal cortex differences in orbital, middle, and 
superior regions nicely confirmed earlier work (e.g. (8, 15)). These regions are important in cognitive processes related to 
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reward and punishment, emotional processing, response inhibition, and attention - all known to be deficient in ADHD (33-
35). Few studies yet have implicated structural differences in the cingulate cortex, an important structure linked to 
executive functioning and emotion (36), in ADHD (7, 37). Findings for the temporal cortex are particularly interesting, 
because both surface area and thickness were affected. The functions of this region are diverse, it seems to be involved in 
semantic memory, processing of abstract concepts, but also in attention, emotion processing and control (38). Integrating 
the current findings with our earlier subcortical results (9), the multitude of findings for brain regions involved in emotion 
processing is intriguing. In view of this, the network of orbito-frontal cortex, cingulate, and amygdala could be particularly 
interesting for future research (39, 40), as it may underlie the deficient emotional self-regulation often observed among 
ADHD patients (33). 
Effect sizes of the observed brain differences were small, which is similar to our earlier findings for subcortical volumes and 
ICV in ADHD (Figure 1) and comparable to effect sizes seen in other psychiatric disorders studied in ENIGMA (23, 24). 
Whether this reflects phenotypic heterogeneity, with only a subgroup of patients showing reduced brain structure of 
large(r) effect size, or homogeneously small effects existing in the majority of patients remains to be investigated. Effects 
were not driven by IQ. Findings in several areas seemed to scale with the severity of hyperactivity/impulsivity in patients, 
but the heterogeneity of assessment instruments limited the power of this analysis. As in our earlier analysis of subcortical 
volumes and ICV, we did not find any significant associations between psychostimulant medication and cortical dimensions, 
neither in case-control nor in population-based designs. However, given our observational design and reliance on legacy 
data, we would not want to draw any definite conclusions from those results. 
Looking across the lifespan, all case-control differences were most pronounced in children and non-significant in 
adolescents and adults. The same phenomenon, albeit attenuated, was seen in our recent cross-sectional study of ICV and 
subcortical structures (9) (Figure 1). Post-hoc analysis of potential differences in effect sizes across the three age groups in 
the current study confirmed age-related attenuation of effects for several structures. Those findings are in line with an 
earlier longitudinal study, where case-control differences in cortical thickness observed in children attenuated with 
increasing age, suggesting a delayed cortical maturation (41). An alternative explanation for the age-related differences 
might be the existence of subgroups; the childhood patient group is likely to consist of a mix of individuals who will persist 
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and remit in adulthood, while the adult group consists largely of persisters. We cannot yet rule out low power as a reason 
for not detecting significant effects in the older subgroups, which were half the size of the children’s group, and these initial 
findings concerning apparent differences across the lifespan should be confirmed in longitudinal studies. 
The case-control differences observed in the childhood sample did not seem to be influenced by comorbidity. However, we 
noticed that the comorbidity rate in this subset was relatively low (39%). There could be several reasons for that. First, the 
sample we used in our analysis of comorbidity was very young (4-14 years), as we only focused on the subsample with 
significant case-control differences. The relatively young age could explain the lower than expected comorbidity rate, as 
children might simply not yet have developed some of the frequent comorbid psychiatric disorders (e.g. substance use 
disorders). In comparison, Taurines and coworkers (2010) (42) described in their review that 73% of 6-18 year olds with 
ADHD had one or more comorbid disorders. A second reason could lie in the fact that we are dealing with research 
diagnoses, in which comorbidity assessments were often limited to checking in- and exclusion criteria for a specific study 
aim. This is a clear limitation of dealing with legacy data from multiple different sites, where different protocols and 
different instruments of assessment of comorbidity and symptom severity were used. We adjusted our design accordingly 
and concentrated only on the three most frequent comorbidities, defining those as ever or never experienced.   
Although our study was not designed to study causality, our results may shed some light on the issue of whether brain 
differences are a consequence of living with the disorder, or are a risk factor for the disorder. Our family analysis showed 
unaffected siblings of cases, i.e. those without a diagnosis and with levels of ADHD symptoms comparable to healthy 
controls, to have similar surface area differences from controls as their affected siblings. In addition, the relationship 
between ADHD symptoms and cortical phenotypes also held in the general population. Here, the dimensional assessment 
of attention problems was related to brain morphology in a linear fashion, suggesting the phenotype and underlying brain 
morphology to be independent of clinical diagnosis, operating along a continuum. The two different approaches show 
cortical alterations in ADHD-related regions to occur independent of diagnosis. The overlap between the findings from the 
different approaches was, however, not complete. Future studies could perform more direct comparisons between case-
control and population samples using e.g. conjunction analysis (43). The two different approaches show cortical alterations 
in ADHD-related regions to occur independent of diagnosis, indicating that they are neither necessary nor sufficient to 
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cause the disorder. The overlap between the findings from the different approaches was, however, not complete. Future 
studies could perform more direct comparisons between case-control and population samples using e.g. conjunction 
analysis (41). In such a design it would be interesting to test the liability-threshold model, to better understand which 
factors contribute to liability for the disorder. Also, whether the observed brain differences relative to controls are indeed 
risk factors for ADHD, remains to be investigated in prospective longitudinal designs. Future imaging genetics studies might 
further clarify the neurobiological pathways and mechanisms underlying cortical differences in ADHD. While genetic 
information is not available in sufficient numbers from ENIGMA-ADHD, the ENIGMA Genetics Working Group recently 
identified genetic factors determining cortical surface area and thickness in a largely healthy population (18). Those genetic 
factors might in turn constitute risk factors for ADHD given recent finding of genetic overlap between the genetic 
contribution to ADHD and to the total surface area of the cortex. As we have recently shown for subcortical volumes and 
intracranial volume, further work might delineate the individual genes or gene networks underlying such genetic overlap 
(Klein et al., Am. J. Psychiatry, in press; see also (44)). 
The current study has several strengths and limitations. Our major strength lies in the large sample sizes in both the clinical 
(n=4180) and population-based (n=2707) samples, along with the use of harmonized segmentation protocols, which 
provided unprecedented power to detect effects. Another strength is the split-half validation combined with stringent 
multiple comparison correction, showing that our findings – despite small effect sizes – are stable. Also, results from the 
population study suggest little effect of motion during scanning on our cortical regions of interest. The combination of case-
control with family- and population-based designs to identify mechanisms is an additional strength. A limitation is that we 
relied on legacy data in ENIGMA-ADHD, so the participating studies differ somewhat in their aims, methods, and 
assessments. Given this heterogeneity, our findings might underestimate the true effects, and we may have missed effects 
of comorbidity, medication, and symptom severity due to insufficient power. The limited sample size of the family study 
together with  the small effect sizes for brain differences is probably the reason why the results of the family study found 
the expected staircase effect, at a trend level only. 
In light of the findings from the current and the earlier (9) ENIGMA studies of ADHD, what should future neuroimaging 
studies in ADHD look like? Effect sizes observed are small (i.e. Cohen’s d=-0.21), with largest effects for measures of total 
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brain volume and surface area in this and our previous study (9). Also, effects are restricted to childhood despite persistent 
ADHD diagnosis in adolescents and adults. Future studies should answer the question, whether (regional) effect sizes are 
comparable in everyone, or whether subgroups exist, in which certain regional effect sizes are more pronounced. This could 
be examined using clustering algorithms, such as community detection, and machine learning (45). An analysis of particular 
interest would be the comparison between children who remit in adulthood and those who persist. In-depth analysis of 
adult persisters versus remitters could add to our understanding of the null findings in adults, as it seems counterintuitive 
that the persisters, believed to be more severely affected, show no apparent signs of brain differences in adulthood, but the 
mixed group of remitters and persisters in the childhood group does. Subgroups may also provide information on 
comorbidity and links to symptom severity in the different behavioral domains of ADHD. Most importantly, longitudinal 
studies are needed to study the processes that lead to the apparent reductions of case-control effects from childhood to 
adolescence and adulthood; only very few longitudinal samples for ADHD are currently available (15, 29).  We should also 
not forget that the segmentation used in the current study is based on classical neuroanatomical divisions rather than a 
partitioning based on biological functions (44, 46). Other cortical phenotypes such as gyrification (47), or more 
sophisticated methods to define regional gray matter structure, and analyses of other brain measures to be captured by 
neuroimaging in large sample sizes (e.g., white matter integrity (48); resting state functional MRI (49)) may help us find the 
presumed case-control differences in adults (50, 51). 
In conclusion, we identify, for the first time, cortical phenotypes affected in ADHD that are robust, and show an association 
with ADHD beyond narrowly-defined clinical diagnoses. Our work suggests them to behave as endophenotypes and extends 
the evidence for ADHD as a continuous trait in the population from behavioral measures and genetics (52) to neuroimaging 
phenotypes. Future studies should clarify individual lifespan trajectories and identify the underlying genetic and 
environmental factors shaping these trajectories. 
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FIGURE LEGENDS 
FIGURE 1. Subcortical and cortical brain differences across the lifespan. 
A. Displayed on the y-axis are the Cohen’s d effect sizes with error bars showing the 95% confidence intervals for case-
control differences in ENIGMA-ADHD cortical and subcortical structural features stratified by age group: children of 14 years 
of age and younger, adolescents from age 15 to 21 years, and adults older than 21 years. All regions displayed showed 
significant case-control differences in children; in analyses of cortical and subcortical features, no significant effects were 
seen in adolescents or adults. This is reflected in the effects sizes shown, all of which are significant for children but not for 
adolescent and adult groups, except for the hippocampus, which shows significance also in the adolescent group. B. 
Displayed are the heatmaps of validated case-control differences in the childhood subset for both surface area (left) and 
thickness (right) in both hemispheres. 
 
 
FIGURE 2. Bar graphs showing results of familiality analyses in the ADHD-affected cortical regions in the NeuroIMAGE 
datasets (n=506). Displayed are the cortical surface areas showing effects of familiality in the NeuroIMAGE datasets. For 
these regions, unaffected siblings differed from healthy controls (Meff-corrected results). Cortical values are adjusted for 
age, gender, ICV and site. 
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Table 1. Mega-analysis of case-control cortical surface area differences in children of 14 years of age and younger in 
ENIGMA-ADHD.  
Cortical region Controls (N) ADHD (N) Cohen's d 
(standard error) 
95% confidence 
interval 
p-value FDR p-value 
total surface areaa 1048 1081 -0.21 (0.04) -0.29 to -0.12 <0.001 <0.001 
superior frontal gyrusa 1044 1074 -0.19 (0.04) -0.28 to -0.11 <0.001 <0.001 
lateral orbitofrontal cortexa 1047 1081 -0.17 (0.04) -0.26 to -0.09 <0.001 <0.001 
medial orbitofrontal cortex 1039 1070 -0.16 (0.04) -0.24 to -0.07 <0.001 0.002 
posterior cingulate cortexa 1042 1078 -0.16 (0.04) -0.25 to -0.08 <0.001 0.002 
rostral anterior cingulate cortexa 1041 1067 -0.16 (0.04) -0.25 to -0.08 <0.001 0.002 
superior temporal gyrus 987 993 -0.15 (0.05) -0.24 to -0.07 <0.001 0.003 
caudal middle frontal gyrusa 1046 1077 -0.15 (0.04) -0.23 to -0.06 <0.001 0.003 
fusiform gyrus 1043 1075 -0.13 (0.04) -0.21 to -0.04 0.004 0.01 
isthmus cingulate cortex 1040 1079 -0.13 (0.04) -0.22 to -0.05 0.002 0.008 
middle temporal gyrusa 1001 1024 -0.13 (0.04) -0.22 to -0.04 0.004 0.01 
rostral middle frontal gyrus 1044 1079 -0.13 (0.04) -0.21 to -0.04 0.004 0.01 
supramarginal gyrus 1036 1063 -0.13 (0.04) -0.22 to -0.05 0.002 0.008 
inferior parietal cortex 1041 1078 -0.12 (0.04) -0.20 to -0.03 0.009 0.02 
inferior temporal gyrus 1041 1064 -0.12 (0.04) -0.21 to -0.04 0.005 0.01 
lateral occipital cortex 1047 1078 -0.12 (0.04) -0.21 to -0.04 0.005 0.01 
precuneus 1044 1080 -0.12 (0.04) -0.20 to -0.03 0.008 0.02 
superior parietal cortex 1045 1073 -0.12 (0.04) -0.21 to -0.04 0.004 0.01 
insula 1042 1078 -0.12 (0.04) -0.21 to -0.04 0.006 0.01 
banks of superior temporal sulcus 974 999 -0.10 (0.05) -0.19 to -0.01 0.02 0.04 
pars triangularis of inferior frontal 
gyrus 
1048 1074 -0.10 (0.04) -0.18 to -0.01 0.02 0.04 
postcentral gyrus 1032 1060 -0.10 (0.04) -0.18 to -0.01 0.03 0.05 
precentral gyrus 1041 1064 -0.10 (0.04) -0.19 to -0.02 0.02 0.03 
temporal pole 1043 1075 -0.10 (0.04) -0.18 to -0.01 0.03 0.04 
Note: Displayed are the significant regions surviving correction for multiple comparisons with FDR q-value<0.05. Regions are 
sorted based on the effect size of the difference between cases and controls (Cohen’s d), with the regions with the largest 
effects on top. Regions are the average of left and right hemisphere surface area. Model is adjusted for age, sex, intracranial 
volume (ICV), and site. aregions surviving validation (see also ST15). For the full results please see ST4. 
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Table 2. Mega-analysis of case-control cortical thickness differences in children of 14 years of age and younger in ENIGMA-
ADHD.  
  Controls (N) ADHD (N) Cohen's d 
(standard error) 
95% 
confidence 
interval 
p-value FDR p-
value 
temporal polea 1042 1075 -0.18 (0.04) -0.27 to -0.10 <0.001 0.001 
fusiform gyrusa 1044 1077 -0.17 (0.04) -0.25 to -0.08 <0.001 0.003 
precentral gyrus 1040 1064 -0.16 (0.04) -0.25 to -0.07 <0.001 0.003 
parahippocampal gyrus 1041 1076 -0.15 (0.04) -0.23 to -0.06 <0.001 0.008 
Note: Displayed are the significant regions surviving correction for multiple comparisons with FDR q-value<0.05. Regions are 
sorted based on the effect size of the difference between cases and controls (Cohen’s d), with the regions with the largest 
effects on top. Regions are the average of left and right hemisphere thickness measures. Model is adjusted for age, sex and 
site. aregions surviving validation (see also ST16). For the full results please see ST10. 
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Table 3. Associations between validated cortical regions and CBCL syndrome scale attention problems in Generation-R. 
Cortical region B SE CI lower CI upper β p-value 
FDR p-
value 
Surface area        
caudal middle frontal gyrus -14.10 5.49 -24.87 -3.33 -0.04 0.01 0.03 
lateral orbitofrontal cortex -8.28 5.01 -18.10 1.54 -0.02 0.10 0.11 
middle temporal gyrus -13.63 5.86 -25.12 -2.14 -0.03 0.02 0.04 
posterior cingulate cortex -5.02 2.42 -9.77 -0.27 -0.03 0.04 0.06 
rostral anterior cingulate cortex -3.50 1.93 -7.29 0.29 -0.03 0.07 0.09 
superior frontal gyrus -7.16 11.93 -30.55 16.24 -0.01 0.55 0.55 
total surface area 
-323.79 77.50 -475.75 -171.82 -0.04 <0.001 <0.001 
total surface area (residualized*) 
-291.62 77.43 -443.44 -139.79 -0.07 <0.001 <0.001 
Thickness        
fusiform gyrus 0.004 0.002 0.000 0.01 0.04 0.05 0.054 
temporal pole 0.01 0.01 -0.001 0.03 0.04 0.07 0.07 
Note: Regions are the average of left and right hemisphere surface area, and are the regions showing significant group 
differences in split-half analyses (ST15 and ST16). Model is adjusted for age, sex, and ethnic background. ICV is also included 
as a covariate in the surface area analysis. B is the unstandardized regression coefficient for the square root transformed 
CBCL syndrome scale attention problems score, and CI is the 95% confidence interval of that regression coefficient. β is the 
standardized regression coefficient. *Given the high correlation between total surface area and ICV, we also tested a model 
where total surface area was first regressed on ICV, and the resulting residuals were used in the model described above, 
but without entering ICV. This shows that multicolinearity is not driving the effects. p-values in bold are considered 
significant, surviving correction for multiple comparisons with FDR q-value<0.05. 
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Figure 1 
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Figure 2 
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